Finance Watch: Genesis, Rapport, Cellares Raise Venture Capital Mega-Rounds

Founder Launched With A $29.6m VC Fund

Private Company Edition: Genesis raised $200m, Rapport brought in $150m and Cellares closed a $255m round. Also, Ferring got $300m up front in a royalty deal, Fore Biotherapeutics raised a $75m series D and Vaxxas won a $3.67m Wellcome grant to advance a next-generation typhoid vaccine.

Finance Watch Private Company
• Source: Shutterstock

Venture capital funding for biopharmaceutical companies overall may be down in 2023, but that does not mean that investors have stopped placing big bets on the industry. Three companies announced recent VC mega-rounds of greater than $100m – Genesis Therapeutics with a $200m series B financing, Rapport Therapeutics with a $150m series B and Cellares with a $255m series C round.

VC investment in biopharma firms rose slightly from the first quarter to second quarter, from $4.9bn to $5bn, but the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Financing

More from Business

In Brief: Sanofi Cements Support For Adagene

 
• By 

Deal Snapshot: The French drugmaker has been shifting its investments away from cancer to focus on immunology and inflammation but it continues to seek out interesting early-stage oncology assets.

In Vivo CAR-T Interest Grows With AbbVie Acquisition

 

Acquiring Capstan gives AbbVie a stake in two competing in vivo CAR-T delivery platforms, with the field's first readouts expected in 2026.

Stock Watch: Syncona’s Wild Ride Exposes Suspect Strategies

 
• By 

A track record of positive portfolio performance is described as an investment management skill. Taking difficult divestment decisions early, in challenging markets and outperforming benchmarks, are hallmarks of this skill. Syncona and Woodford Patient Capital offer useful case studies.